We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $0.25 | — | — | $80.2M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.16 | — | — | $62.47M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $0.03 | — | — | $175.27M |
Consensus PT $17 · 7 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 12. 03. | Leerink Partners | — | 투자의견 하향 | Outperform → Market Perform | — | Leerink Partners: Outperform → Market Perform |
| 2025. 11. 07. | Jefferies | — | 투자의견 상향 | Hold → Buy | — | Jefferies: Hold → Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.07 | — | — | $107.5M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 3,428,705 | $50.81B | 0.04% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,962,742 | $31.31B | 0.05% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Stored first · Google News · Yahoo Finance (English)
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison Intellectia AI
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) ChartMill
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
Discipline and Rules-Based Execution in AUPH Response Stock Traders Daily
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO - Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO Stock Titan